| scholarly article | Q13442814 |
| P356 | DOI | 10.1067/MCP.2000.106464 |
| P698 | PubMed publication ID | 10824625 |
| P2093 | author name string | Turgeon J | |
| Jobin J | |||
| Hamelin BA | |||
| Poirier P | |||
| Bouayad A | |||
| Dumesnil J | |||
| Desgagnés P | |||
| Allaire J | |||
| Méthot J | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | histamine antagonist | Q324089 |
| P304 | page(s) | 466-477 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity | |
| P478 | volume | 67 |
| Q42284131 | A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study |
| Q24602122 | A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics |
| Q36717181 | A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women |
| Q37265701 | Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans |
| Q34466778 | Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system |
| Q37710941 | Benefits and risks associated with beta-blocker prophylaxis in noncardiac surgery. |
| Q89850997 | CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis |
| Q34831245 | Cardiac drug-psychotropic drug update |
| Q36762067 | Clinically important interaction between metoprolol and propafenone |
| Q33898184 | Coprescription of tamoxifen and medications that inhibit CYP2D6. |
| Q34346501 | Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients |
| Q36732076 | Differential genotype dependent inhibition of CYP2C9 in humans |
| Q35774851 | Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? |
| Q91620854 | Drug-drug-gene interactions and adverse drug reactions |
| Q39062681 | Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients |
| Q44547822 | Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients |
| Q53257546 | Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers. |
| Q44168669 | Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers |
| Q53203053 | Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. |
| Q35112394 | Extended-Release Metoprolol Succinate in Chronic Heart Failure |
| Q44100761 | Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? |
| Q88154082 | Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model |
| Q54572507 | Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. |
| Q37207816 | Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach |
| Q36562502 | Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone |
| Q84252582 | In silico and in vivo evaluation of flavonoid extracts on CYP2D6-mediated herb-drug interaction |
| Q34742927 | Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports |
| Q35862163 | Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial |
| Q35097430 | Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? |
| Q35038052 | Pharmacogenetics in drug regulation: promise, potential and pitfalls |
| Q39035865 | Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report |
| Q36365500 | Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. |
| Q60046975 | Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit |
| Q36662893 | Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments |
| Q35934105 | Pharmacokinetics and pharmacodynamics of beta blockers in heart failure |
| Q47404372 | Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. |
| Q34567323 | Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. |
| Q37611786 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. |
| Q39730908 | Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions |
| Q79323979 | Screening of drug metabolism by CE |
| Q37956954 | Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs |
| Q47861202 | Single-Dose Pharmacokinetic Study of Diphenhydramine HCl in Children and Adolescents |
| Q32103802 | Summary of information on human CYP enzymes: human P450 metabolism data |
| Q46776670 | The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol |
| Q43233463 | Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction |
| Q50707361 | Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. |
| Q35045435 | Upregulation of cytochromes P450 2B in rat liver by orphenadrine |
Search more.